| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 15 | 2023 | 51 | 4.560 |
Why?
|
| Clinical Trials as Topic | 8 | 2023 | 455 | 2.270 |
Why?
|
| Quality Assurance, Health Care | 6 | 2021 | 255 | 2.210 |
Why?
|
| Neoplasms | 14 | 2024 | 1364 | 2.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2024 | 58 | 1.800 |
Why?
|
| Hodgkin Disease | 10 | 2019 | 55 | 1.700 |
Why?
|
| Radiosurgery | 3 | 2021 | 62 | 1.600 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2024 | 35 | 1.530 |
Why?
|
| Diagnostic Imaging | 3 | 2018 | 264 | 1.210 |
Why?
|
| Radiotherapy, Conformal | 4 | 2023 | 19 | 1.130 |
Why?
|
| Radiation Injuries | 5 | 2019 | 66 | 1.110 |
Why?
|
| Clinical Protocols | 5 | 2018 | 134 | 1.090 |
Why?
|
| Radiotherapy | 4 | 2019 | 64 | 1.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2022 | 448 | 1.010 |
Why?
|
| Influenza, Human | 3 | 2017 | 208 | 0.990 |
Why?
|
| Prostatic Neoplasms | 6 | 2018 | 418 | 0.960 |
Why?
|
| Lung Neoplasms | 8 | 2022 | 674 | 0.930 |
Why?
|
| Radiation Tolerance | 4 | 2024 | 52 | 0.930 |
Why?
|
| Proton Therapy | 3 | 2021 | 8 | 0.900 |
Why?
|
| Pandemics | 3 | 2017 | 671 | 0.830 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 160 | 0.780 |
Why?
|
| Radiotherapy Dosage | 12 | 2024 | 84 | 0.740 |
Why?
|
| Insurance Carriers | 1 | 2021 | 7 | 0.720 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2018 | 35 | 0.720 |
Why?
|
| Hematuria | 1 | 2021 | 21 | 0.700 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 18 | 0.690 |
Why?
|
| Humans | 72 | 2024 | 63445 | 0.690 |
Why?
|
| Disaster Planning | 3 | 2017 | 55 | 0.680 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 43 | 0.680 |
Why?
|
| Civil Defense | 2 | 2017 | 15 | 0.680 |
Why?
|
| Nephrectomy | 1 | 2021 | 91 | 0.670 |
Why?
|
| Developing Countries | 2 | 2017 | 94 | 0.640 |
Why?
|
| Tissue Expansion Devices | 3 | 2017 | 17 | 0.600 |
Why?
|
| International Cooperation | 3 | 2018 | 90 | 0.600 |
Why?
|
| Palliative Care | 1 | 2021 | 230 | 0.590 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2018 | 14 | 0.590 |
Why?
|
| Child | 20 | 2024 | 4526 | 0.580 |
Why?
|
| Lymphoma | 1 | 2019 | 103 | 0.570 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2024 | 178 | 0.570 |
Why?
|
| Mass Vaccination | 1 | 2017 | 10 | 0.550 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 297 | 0.530 |
Why?
|
| Breast Neoplasms | 6 | 2015 | 1198 | 0.520 |
Why?
|
| Pharmacies | 1 | 2016 | 36 | 0.500 |
Why?
|
| Heart | 1 | 2018 | 283 | 0.500 |
Why?
|
| Radiodermatitis | 2 | 2016 | 11 | 0.500 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2022 | 166 | 0.500 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 125 | 0.450 |
Why?
|
| Public Health | 1 | 2016 | 187 | 0.450 |
Why?
|
| Film Dosimetry | 1 | 2014 | 9 | 0.440 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1553 | 0.440 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 308 | 0.440 |
Why?
|
| Lung | 2 | 2021 | 956 | 0.430 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 13 | 0.430 |
Why?
|
| Diaphragm | 1 | 2014 | 22 | 0.430 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 266 | 0.420 |
Why?
|
| Tissue Expansion | 3 | 2020 | 24 | 0.410 |
Why?
|
| Androgens | 2 | 2010 | 48 | 0.380 |
Why?
|
| Perfusion Imaging | 1 | 2012 | 20 | 0.370 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 1469 | 0.370 |
Why?
|
| Oximetry | 1 | 2012 | 48 | 0.370 |
Why?
|
| Neuropilin-2 | 2 | 2024 | 40 | 0.370 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 67 | 0.360 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 209 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 68 | 0.350 |
Why?
|
| Male | 30 | 2024 | 29891 | 0.320 |
Why?
|
| Whole-Body Irradiation | 3 | 2024 | 33 | 0.320 |
Why?
|
| Quality of Health Care | 1 | 2014 | 519 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 348 | 0.310 |
Why?
|
| Female | 31 | 2024 | 32880 | 0.300 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 5 | 0.300 |
Why?
|
| Anilides | 1 | 2008 | 18 | 0.300 |
Why?
|
| Integrins | 3 | 2016 | 109 | 0.300 |
Why?
|
| United States | 10 | 2020 | 7843 | 0.300 |
Why?
|
| Nitriles | 1 | 2008 | 70 | 0.290 |
Why?
|
| Radiation Injuries, Experimental | 2 | 2020 | 9 | 0.290 |
Why?
|
| Young Adult | 10 | 2021 | 4694 | 0.290 |
Why?
|
| Prognosis | 5 | 2022 | 1748 | 0.290 |
Why?
|
| Adolescent | 11 | 2021 | 6245 | 0.280 |
Why?
|
| Anus Neoplasms | 2 | 2017 | 25 | 0.260 |
Why?
|
| Child, Preschool | 9 | 2021 | 1990 | 0.250 |
Why?
|
| Medical Oncology | 2 | 2023 | 66 | 0.250 |
Why?
|
| Chemoradiotherapy | 4 | 2020 | 67 | 0.250 |
Why?
|
| Receptors, Androgen | 3 | 2016 | 31 | 0.240 |
Why?
|
| Influenza Vaccines | 2 | 2017 | 99 | 0.240 |
Why?
|
| Terminology as Topic | 2 | 2017 | 141 | 0.240 |
Why?
|
| Phantoms, Imaging | 2 | 2018 | 214 | 0.230 |
Why?
|
| Ammonia | 1 | 2024 | 14 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 259 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2016 | 83 | 0.220 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 27 | 0.220 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 136 | 0.220 |
Why?
|
| Nitric Oxide | 1 | 2024 | 174 | 0.210 |
Why?
|
| Adenoma | 1 | 2023 | 70 | 0.200 |
Why?
|
| Aged | 14 | 2023 | 14447 | 0.200 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 663 | 0.200 |
Why?
|
| Feces | 1 | 2023 | 112 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2018 | 1644 | 0.200 |
Why?
|
| Colonoscopy | 1 | 2023 | 100 | 0.200 |
Why?
|
| Neoplastic Stem Cells | 1 | 2024 | 203 | 0.200 |
Why?
|
| Oxidative Stress | 1 | 2024 | 298 | 0.190 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 53 | 0.190 |
Why?
|
| Prospective Studies | 5 | 2023 | 3293 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 213 | 0.190 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 2458 | 0.180 |
Why?
|
| Vincristine | 5 | 2022 | 27 | 0.180 |
Why?
|
| Sarcoma | 2 | 2018 | 36 | 0.180 |
Why?
|
| Medulloblastoma | 1 | 2021 | 12 | 0.180 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 509 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 5462 | 0.180 |
Why?
|
| Insurance Coverage | 1 | 2021 | 100 | 0.170 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 8 | 0.170 |
Why?
|
| Cisplatin | 6 | 2018 | 139 | 0.170 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2020 | 8 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 276 | 0.170 |
Why?
|
| Adult | 12 | 2021 | 16824 | 0.170 |
Why?
|
| RNA | 1 | 2023 | 423 | 0.160 |
Why?
|
| Insurance, Health | 1 | 2021 | 152 | 0.160 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 208 | 0.160 |
Why?
|
| Meningeal Neoplasms | 2 | 2015 | 59 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 52 | 0.160 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 17 | 0.160 |
Why?
|
| Doxorubicin | 6 | 2020 | 99 | 0.160 |
Why?
|
| Down-Regulation | 2 | 2018 | 319 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 189 | 0.160 |
Why?
|
| Subcutaneous Fat | 1 | 2020 | 47 | 0.160 |
Why?
|
| Middle Aged | 13 | 2023 | 17613 | 0.160 |
Why?
|
| Rad51 Recombinase | 1 | 2019 | 29 | 0.150 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 242 | 0.150 |
Why?
|
| Wilms Tumor | 1 | 2018 | 4 | 0.150 |
Why?
|
| Mice | 9 | 2024 | 10844 | 0.150 |
Why?
|
| Infratentorial Neoplasms | 1 | 2018 | 4 | 0.150 |
Why?
|
| Radiometry | 1 | 2018 | 36 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2024 | 3035 | 0.140 |
Why?
|
| Brain Stem | 1 | 2018 | 28 | 0.140 |
Why?
|
| Combined Modality Therapy | 7 | 2018 | 373 | 0.140 |
Why?
|
| Oligopeptides | 1 | 2018 | 132 | 0.140 |
Why?
|
| Choice Behavior | 2 | 2016 | 83 | 0.140 |
Why?
|
| Societies, Scientific | 1 | 2017 | 36 | 0.140 |
Why?
|
| Cyclophosphamide | 5 | 2020 | 82 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2018 | 195 | 0.140 |
Why?
|
| Skin | 3 | 2018 | 373 | 0.140 |
Why?
|
| Mammaplasty | 2 | 2016 | 48 | 0.130 |
Why?
|
| Vaccination Coverage | 1 | 2016 | 8 | 0.130 |
Why?
|
| Transfection | 1 | 2018 | 694 | 0.130 |
Why?
|
| Cell Survival | 1 | 2018 | 575 | 0.130 |
Why?
|
| Beta Particles | 1 | 2016 | 2 | 0.130 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 16 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 564 | 0.120 |
Why?
|
| Immunization | 1 | 2016 | 133 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 724 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 864 | 0.120 |
Why?
|
| Information Management | 1 | 2015 | 12 | 0.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 90 | 0.120 |
Why?
|
| Mastectomy | 2 | 2014 | 58 | 0.120 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2187 | 0.120 |
Why?
|
| Etoposide | 4 | 2018 | 34 | 0.120 |
Why?
|
| Meningioma | 1 | 2015 | 60 | 0.120 |
Why?
|
| Oxygen | 2 | 2016 | 317 | 0.120 |
Why?
|
| Pharmacists | 1 | 2016 | 127 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2013 | 277 | 0.110 |
Why?
|
| RNA Interference | 1 | 2018 | 618 | 0.110 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2014 | 2 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 712 | 0.110 |
Why?
|
| Learning | 1 | 2016 | 182 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2015 | 118 | 0.110 |
Why?
|
| Global Health | 1 | 2015 | 183 | 0.110 |
Why?
|
| Animals | 9 | 2024 | 20663 | 0.110 |
Why?
|
| Data Collection | 1 | 2015 | 383 | 0.110 |
Why?
|
| Osteolysis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2014 | 44 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 29 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2021 | 6658 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2681 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 149 | 0.100 |
Why?
|
| Prednisone | 3 | 2020 | 85 | 0.100 |
Why?
|
| Integrin beta1 | 1 | 2013 | 32 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 2 | 2004 | 16 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2013 | 112 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 598 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2014 | 374 | 0.100 |
Why?
|
| Credentialing | 1 | 2012 | 15 | 0.090 |
Why?
|
| Thalidomide | 1 | 2012 | 34 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 360 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2008 | 52 | 0.090 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 76 | 0.090 |
Why?
|
| Decision Making | 1 | 2015 | 407 | 0.090 |
Why?
|
| Infant | 5 | 2018 | 1645 | 0.090 |
Why?
|
| Bleomycin | 3 | 2018 | 34 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1094 | 0.090 |
Why?
|
| Medical Informatics | 1 | 2012 | 73 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2012 | 206 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2020 | 5680 | 0.080 |
Why?
|
| Fluorouracil | 3 | 2017 | 66 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 59 | 0.080 |
Why?
|
| HIV Infections | 1 | 2016 | 969 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 772 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2022 | 255 | 0.080 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2010 | 142 | 0.080 |
Why?
|
| Paclitaxel | 2 | 2012 | 99 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 172 | 0.080 |
Why?
|
| Brain | 1 | 2017 | 1552 | 0.080 |
Why?
|
| Radiation, Ionizing | 1 | 2008 | 15 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 2175 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1147 | 0.070 |
Why?
|
| Cytarabine | 3 | 2018 | 36 | 0.070 |
Why?
|
| Fibronectins | 1 | 2008 | 43 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 574 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 209 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2010 | 305 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 851 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2024 | 281 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1654 | 0.070 |
Why?
|
| Cetuximab | 2 | 2017 | 8 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 341 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 83 | 0.070 |
Why?
|
| Remission Induction | 3 | 2014 | 148 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2010 | 988 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2004 | 345 | 0.060 |
Why?
|
| Dexamethasone | 2 | 2018 | 205 | 0.060 |
Why?
|
| Mice, Hairless | 2 | 2016 | 19 | 0.060 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 13 | 0.060 |
Why?
|
| Bone Neoplasms | 2 | 2018 | 125 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2018 | 1358 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 70 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 88 | 0.050 |
Why?
|
| Fibrosis | 2 | 2016 | 160 | 0.050 |
Why?
|
| Immunochemistry | 1 | 2023 | 10 | 0.050 |
Why?
|
| Occult Blood | 1 | 2023 | 19 | 0.050 |
Why?
|
| RNA, Small Untranslated | 1 | 2023 | 19 | 0.050 |
Why?
|
| Recurrence | 2 | 2018 | 641 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2018 | 1008 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 123 | 0.050 |
Why?
|
| Lymphocyte Transfusion | 1 | 2002 | 37 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 525 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 200 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 57 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 49 | 0.050 |
Why?
|
| Time Factors | 2 | 2020 | 3768 | 0.040 |
Why?
|
| Massachusetts | 2 | 2018 | 2075 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2002 | 168 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2010 | 583 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 322 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 978 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 25 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 87 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2016 | 2109 | 0.040 |
Why?
|
| Platinum | 1 | 2019 | 20 | 0.040 |
Why?
|
| Neuropilins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2019 | 28 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2002 | 352 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1558 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 165 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 58 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 507 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2018 | 5 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2018 | 3 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2018 | 7 | 0.040 |
Why?
|
| Extremities | 1 | 2018 | 43 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2018 | 87 | 0.040 |
Why?
|
| Photons | 1 | 2018 | 23 | 0.040 |
Why?
|
| Texas | 1 | 2018 | 57 | 0.040 |
Why?
|
| Florida | 1 | 2018 | 48 | 0.040 |
Why?
|
| Uncertainty | 1 | 2018 | 37 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2018 | 15 | 0.040 |
Why?
|
| Mass Screening | 1 | 2023 | 691 | 0.040 |
Why?
|
| Salvage Therapy | 2 | 2012 | 75 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 198 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2018 | 47 | 0.040 |
Why?
|
| SEER Program | 1 | 2018 | 74 | 0.040 |
Why?
|
| Leukemia | 1 | 2018 | 62 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2018 | 42 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 39 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 73 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2018 | 52 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 54 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 490 | 0.030 |
Why?
|
| Necrosis | 1 | 2018 | 143 | 0.030 |
Why?
|
| DNA Repair | 1 | 2019 | 248 | 0.030 |
Why?
|
| Wound Healing | 1 | 2018 | 189 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2017 | 21 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 112 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2576 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 429 | 0.030 |
Why?
|
| Habits | 1 | 2016 | 21 | 0.030 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2016 | 12 | 0.030 |
Why?
|
| Skin Ulcer | 1 | 2016 | 14 | 0.030 |
Why?
|
| Edema | 1 | 2016 | 43 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 568 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 730 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 234 | 0.030 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 8 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 27 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1172 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 21 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 202 | 0.030 |
Why?
|
| Reward | 1 | 2016 | 87 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 92 | 0.030 |
Why?
|
| Dopamine | 1 | 2016 | 106 | 0.030 |
Why?
|
| Collagen | 1 | 2016 | 123 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 104 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 777 | 0.030 |
Why?
|
| Concept Formation | 1 | 2015 | 18 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 26 | 0.030 |
Why?
|
| Knowledge | 1 | 2015 | 31 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5354 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 97 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2015 | 59 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 171 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2015 | 122 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 60 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 664 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 116 | 0.030 |
Why?
|
| Reimbursement Mechanisms | 1 | 2014 | 40 | 0.030 |
Why?
|
| Software | 1 | 2017 | 389 | 0.030 |
Why?
|
| Postmenopause | 1 | 2015 | 237 | 0.030 |
Why?
|
| Breast | 1 | 2016 | 183 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 896 | 0.030 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 443 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 60 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 61 | 0.030 |
Why?
|
| Pain Management | 1 | 2015 | 161 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2016 | 295 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 30 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 271 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2013 | 108 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 229 | 0.020 |
Why?
|
| Razoxane | 1 | 2012 | 2 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 222 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 978 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 268 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 519 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 864 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2014 | 211 | 0.020 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2012 | 2 | 0.020 |
Why?
|
| Carboplatin | 1 | 2012 | 43 | 0.020 |
Why?
|
| Metribolone | 1 | 2011 | 3 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 10 | 0.020 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 9 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 68 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 147 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 888 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2012 | 73 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 298 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 1513 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 111 | 0.020 |
Why?
|
| Radiation Dosage | 2 | 2002 | 132 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 422 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1229 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2010 | 19 | 0.020 |
Why?
|
| Carmustine | 1 | 2009 | 11 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1277 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 160 | 0.020 |
Why?
|
| Internationality | 1 | 2009 | 44 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 88 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 39 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 154 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2009 | 62 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 936 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2079 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2570 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 608 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 283 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1079 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2008 | 69 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 937 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 921 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 89 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2004 | 46 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2004 | 124 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 137 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 201 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2002 | 40 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2002 | 73 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 2002 | 102 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2002 | 46 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 284 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 289 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 80 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 278 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2002 | 193 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1377 | 0.010 |
Why?
|